Recent Updates
Recently added Catalysts

AB308

Phase 1

Advanced Solid Tumor | Small molecule | Oncology |Arcus Biosciences, Inc.|Last Updated: Aug 28, 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment94

FDA Designations

No designations recorded

Clinical trial landscape

AB308 · 1 trial · 10 indications

Phase 1 1
NCT04772989A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesAdvanced Solid Tumor
COMPLETED94 Analytics
PHASE1COMPLETED
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Advanced Solid Tumor
NCT0477298994
Unlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of participants with Adverse Events
From first study treatment administration until up to 90 days after the last dose (Approximately 1 year)
Percentage of participants who experience a Dose Limiting Toxicity
From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q4W arm) or Day 42 (Q6W arm)

Secondary Endpoints

Serum concentration of AB308
Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months)
Serum concentration of zimberelimab
Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months)
Percentage of participants with anti-drug antibodies to AB308
Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months)
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Dose Escalation Q3W CohortsEXPERIMENTALEscalating doses of AB308 in combination with zimberelimab (360 mg) will be given every 3 weeks in participants with advanced malignancies.
Dose Escalation Q4W CohortsEXPERIMENTALEscalating doses of AB308 in combination with zimberelimab (480 mg) will be given every 4 weeks in participants with advanced malignancies.
Dose Escalation Q6W CohortEXPERIMENTALSelected dose of AB308 in combination with zimberelimab will be given every 6 weeks in participants with advanced malignancies.
Dose Expansion Cohort 1EXPERIMENTALAB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with in participants with locally advanced or metastatic NSCLC.
Dose Expansion Cohort 2EXPERIMENTALAB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with melanoma.
Dose Expansion Cohort 3EXPERIMENTALAB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer.
Dose Expansion Cohort 4EXPERIMENTALAB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with cervical cancer.
Dose Expansion Cohort 5EXPERIMENTALAB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with hematological malignancies.

Interventions

NameTypeDescription
AB308DRUGAdministered intravenously (IV) as specified in the treatment arm
ZimberelimabDRUGAdministered IV as specified in the treatment arm
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites22

Inclusion Criteria: * Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for particip...

Countries:United StatesPolandSpain
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 9 trials (matched to "Advanced Solid Tumor")

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
AstraZeneca PLCAZN1 - Trastuzumab deruxtecan
Unlock Competitive Intelligence

Frequently asked questions about AB308

What is AB308 used for?

AB308 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is being evaluated in combination with another drug, AB122, in patients with advanced malignancies, including non-small cell lung cancer, melanoma, cervical cancer, multiple myeloma, lymphoma, and certain gastrointestinal cancers.

What does AB308 target?

AB308 is a small molecule, but its specific molecular target has not been disclosed. It is being studied in combination with AB122, which is an anti-PD-1 antibody, for the treatment of advanced solid tumors. The mechanism of action of AB308 is not publicly detailed.

Who makes AB308?

AB308 is being developed by Arcus Biosciences, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol RCUS. Arcus Biosciences is conducting clinical trials to evaluate the safety and efficacy of AB308 in combination with other therapies.

What phase is AB308 in?

AB308 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study evaluating AB308 in combination with AB122 has been completed, but the drug remains in early-stage clinical development.

What clinical trials is AB308 in?

AB308 has been studied in one clinical trial, NCT04772989, titled "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies." This Phase 1 trial enrolled 94 participants and was completed. The study was conducted in the United States, Poland, and Spain.

Is AB308 the same as AB122?

No, AB308 is not the same as AB122. AB308 is a small molecule being developed by Arcus Biosciences, while AB122 is a separate investigational drug, likely an anti-PD-1 antibody. In clinical trials, AB308 is being studied in combination with AB122 to treat advanced solid tumors.